Do analysts recommend MESO or MIRM?

Mirum Pharmaceuticals has a consensus price target of $143.40, indicating a potential upside of 20.46%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Mirum Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.93

Does the media prefer MESO or MIRM?

In the previous week, Mesoblast and Mesoblast both had 10 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 0.78 beat Mesoblast's score of 0.77 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Mirum Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MESO or PTCT?

PTC Therapeutics has a consensus target price of $91.57, suggesting a potential upside of 12.59%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe PTC Therapeutics is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 PTC Therapeutics 2 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.80

Which has better valuation and earnings, MESO or PTCT?

PTC Therapeutics has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $17.20M 122.08 -$102.14M -$0.28 N/A PTC Therapeutics $1.73B 3.90 $682.64M -$2.33 N/A

Does the media prefer MESO or PTCT?

In the previous week, PTC Therapeutics had 7 more articles in the media than Mesoblast. MarketBeat recorded 17 mentions for PTC Therapeutics and 10 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.77 beat PTC Therapeutics' score of 0.57 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive PTC Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MESO or COGT?

Cogent Biosciences has a consensus target price of $43.73, suggesting a potential upside of 16.73%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Cogent Biosciences 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86

Is MESO or COGT more profitable?

Mesoblast's return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Cogent Biosciences N/A -104.27% -54.64%

Does the media refer more to MESO or COGT?

In the previous week, Mesoblast had 7 more articles in the media than Cogent Biosciences. MarketBeat recorded 10 mentions for Mesoblast and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.60 beat Mesoblast's score of 0.77 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Cogent Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate MESO or SRRK?

Scholar Rock has a consensus target price of $56.00, suggesting a potential upside of 2.38%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Scholar Rock 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 4 Strong Buy rating(s) 3.12

Which has better earnings & valuation, MESO or SRRK?

Mesoblast has higher revenue and earnings than Scholar Rock. Mesoblast is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $17.20M 122.08 -$102.14M -$0.28 N/A Scholar Rock N/A N/A -$377.94M -$3.59 N/A

Is MESO or SRRK more profitable?

Mesoblast's return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Scholar Rock N/A -163.52% -96.67%

Does the media prefer MESO or SRRK?

In the previous week, Mesoblast had 1 more articles in the media than Scholar Rock. MarketBeat recorded 10 mentions for Mesoblast and 9 mentions for Scholar Rock. Mesoblast's average media sentiment score of 0.77 beat Scholar Rock's score of 0.02 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Scholar Rock 3 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer LNTH or MESO?

Lantheus presently has a consensus price target of $108.29, suggesting a potential upside of 2.75%. Given Lantheus' stronger consensus rating and higher possible upside, research analysts clearly believe Lantheus is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73 Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has better earnings and valuation, LNTH or MESO?

Lantheus has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.45 $233.56M $4.15 25.40 Mesoblast $17.20M 122.08 -$102.14M -$0.28 N/A

Is LNTH or MESO more profitable?

Lantheus has a net margin of 18.05% compared to Mesoblast's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Mesoblast's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Mesoblast N/A N/A N/A

Does the media favor LNTH or MESO?

In the previous week, Mesoblast had 6 more articles in the media than Lantheus. MarketBeat recorded 10 mentions for Mesoblast and 4 mentions for Lantheus. Lantheus' average media sentiment score of 1.19 beat Mesoblast's score of 0.77 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Mesoblast (MESO) Competitors

$16.22 +0.78 (+5.05%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$16.19 -0.03 (-0.18%)

As of 07/13/2026 07:20 PM Eastern

Compare

MESO vs. MIRM, PTCT, COGT, SRRK, and LNTH

Should you buy Mesoblast stock or one of its competitors? MarketBeat compares Mesoblast with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mesoblast include Mirum Pharmaceuticals (MIRM), PTC Therapeutics (PTCT), Cogent Biosciences (COGT), Scholar Rock (SRRK), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

How does Mesoblast compare to Mirum Pharmaceuticals?

Mesoblast (NASDAQ:MESO) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

In the previous week, Mesoblast and Mesoblast both had 10 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 0.78 beat Mesoblast's score of 0.77 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mesoblast has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

1.4% of Mesoblast shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Mirum Pharmaceuticals has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	122.08	-$102.14M	-$0.28	N/A
Mirum Pharmaceuticals	$521.31M	13.92	-$23.36M	-$13.61	N/A

Mesoblast has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mesoblast's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Mirum Pharmaceuticals has a consensus price target of $143.40, indicating a potential upside of 20.46%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Mesoblast beats Mirum Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Mesoblast compare to PTC Therapeutics?

Mesoblast (NASDAQ:MESO) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, PTC Therapeutics had 7 more articles in the media than Mesoblast. MarketBeat recorded 17 mentions for PTC Therapeutics and 10 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.77 beat PTC Therapeutics' score of 0.57 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
PTC Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Mesoblast has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

PTC Therapeutics has a consensus target price of $91.57, suggesting a potential upside of 12.59%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe PTC Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

PTC Therapeutics has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	122.08	-$102.14M	-$0.28	N/A
PTC Therapeutics	$1.73B	3.90	$682.64M	-$2.33	N/A

Mesoblast has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Mesoblast's return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
PTC Therapeutics	-22.58%	-362.45%	-6.76%

1.4% of Mesoblast shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Mesoblast beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Mesoblast compare to Cogent Biosciences?

Mesoblast (NASDAQ:MESO) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Cogent Biosciences has a consensus target price of $43.73, suggesting a potential upside of 16.73%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Mesoblast's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Cogent Biosciences	N/A	-104.27%	-54.64%

1.4% of Mesoblast shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Mesoblast has higher revenue and earnings than Cogent Biosciences. Mesoblast is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	122.08	-$102.14M	-$0.28	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Mesoblast has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

In the previous week, Mesoblast had 7 more articles in the media than Cogent Biosciences. MarketBeat recorded 10 mentions for Mesoblast and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.60 beat Mesoblast's score of 0.77 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Cogent Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Mesoblast beats Cogent Biosciences on 9 of the 15 factors compared between the two stocks.

How does Mesoblast compare to Scholar Rock?

Mesoblast (NASDAQ:MESO) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Mesoblast's return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Scholar Rock	N/A	-163.52%	-96.67%

Mesoblast has higher revenue and earnings than Scholar Rock. Mesoblast is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	122.08	-$102.14M	-$0.28	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Mesoblast has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

In the previous week, Mesoblast had 1 more articles in the media than Scholar Rock. MarketBeat recorded 10 mentions for Mesoblast and 9 mentions for Scholar Rock. Mesoblast's average media sentiment score of 0.77 beat Scholar Rock's score of 0.02 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Scholar Rock	3 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 10.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Scholar Rock has a consensus target price of $56.00, suggesting a potential upside of 2.38%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Summary

Mesoblast beats Scholar Rock on 9 of the 15 factors compared between the two stocks.

How does Mesoblast compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Lantheus has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.45	$233.56M	$4.15	25.40
Mesoblast	$17.20M	122.08	-$102.14M	-$0.28	N/A

Lantheus has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to Mesoblast's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Mesoblast	N/A	N/A	N/A

In the previous week, Mesoblast had 6 more articles in the media than Lantheus. MarketBeat recorded 10 mentions for Mesoblast and 4 mentions for Lantheus. Lantheus' average media sentiment score of 1.19 beat Mesoblast's score of 0.77 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Lantheus presently has a consensus price target of $108.29, suggesting a potential upside of 2.75%. Given Lantheus' stronger consensus rating and higher possible upside, research analysts clearly believe Lantheus is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Lantheus beats Mesoblast on 12 of the 17 factors compared between the two stocks.

Get Mesoblast News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MESO vs. The Competition

Export

Metric	Mesoblast	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.00B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-57.93	20.85	27.11	24.26
Price / Sales	122.08	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	3.47	8.49	10.75	6.29
Net Income	-$102.14M	$23.83M	$3.58B	$330.66M
7 Day Performance	13.51%	-3.56%	-2.06%	-1.32%
1 Month Performance	16.44%	6.31%	3.32%	-0.64%
1 Year Performance	45.21%	48.30%	26.36%	19.08%

Mesoblast Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MESO Mesoblast	0.8583 of 5 stars	$16.22 +5.1%	N/A	+46.0%	$2.00B	$17.20M	N/A	80	News Coverage Gap Up
MIRM Mirum Pharmaceuticals	2.5449 of 5 stars	$121.71 -0.2%	$143.00 +17.5%	+126.1%	$7.42B	$521.31M	N/A	140
PTCT PTC Therapeutics	2.9906 of 5 stars	$86.01 +0.7%	$91.36 +6.2%	+67.5%	$7.16B	$1.73B	N/A	1,410	Insider Trade
COGT Cogent Biosciences	2.1125 of 5 stars	$39.74 +0.8%	$43.73 +10.0%	+241.2%	$6.82B	N/A	N/A	80
SRRK Scholar Rock	1.7123 of 5 stars	$55.34 +0.8%	$56.00 +1.2%	+46.1%	$6.64B	N/A	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MESO) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mesoblast (MESO) Competitors

MESO vs. MIRM, PTCT, COGT, SRRK, and LNTH

How does Mesoblast compare to Mirum Pharmaceuticals?

Summary

How does Mesoblast compare to PTC Therapeutics?

Summary

How does Mesoblast compare to Cogent Biosciences?

Summary

How does Mesoblast compare to Scholar Rock?

Summary

How does Mesoblast compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mesoblast (MESO) Competitors

MESO vs. MIRM, PTCT, COGT, SRRK, and LNTH

How does Mesoblast compare to Mirum Pharmaceuticals?

Does the media prefer MESO or MIRM?

Which has more volatility & risk, MESO or MIRM?

Do institutionals and insiders believe in MESO or MIRM?

Which has preferable valuation & earnings, MESO or MIRM?

Is MESO or MIRM more profitable?

Do analysts recommend MESO or MIRM?

Summary

How does Mesoblast compare to PTC Therapeutics?

Does the media prefer MESO or PTCT?

Which has more volatility and risk, MESO or PTCT?

Do analysts rate MESO or PTCT?

Which has better valuation and earnings, MESO or PTCT?

Is MESO or PTCT more profitable?

Do institutionals and insiders have more ownership in MESO or PTCT?

Summary

How does Mesoblast compare to Cogent Biosciences?

Do analysts rate MESO or COGT?

Is MESO or COGT more profitable?

Do insiders & institutionals hold more shares of MESO or COGT?

Which has better earnings and valuation, MESO or COGT?

Which has more volatility & risk, MESO or COGT?

Does the media refer more to MESO or COGT?

Summary

How does Mesoblast compare to Scholar Rock?

Is MESO or SRRK more profitable?

Which has better earnings & valuation, MESO or SRRK?

Which has more risk and volatility, MESO or SRRK?

Does the media prefer MESO or SRRK?

Do insiders and institutionals have more ownership in MESO or SRRK?

Do analysts rate MESO or SRRK?

Summary

How does Mesoblast compare to Lantheus?

Which has better earnings and valuation, LNTH or MESO?

Which has more risk & volatility, LNTH or MESO?

Do insiders and institutionals have more ownership in LNTH or MESO?

Is LNTH or MESO more profitable?

Does the media favor LNTH or MESO?

Do analysts prefer LNTH or MESO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools